Singapore General Hospital & Thermo Fisher Scientific Collaborate to Identify the Prevalence of Asian-Specific Genetic Mutati...
November 04 2015 - 6:00PM
Business Wire
Singapore General Hospital (SGH) and Thermo Fisher Scientific
today announced the establishment of a collaborative partnership
that will work to identify cancer genetic mutations linked with
Asian populations on Thermo Fisher’s Ion Torrent next-generation
sequencing (NGS) platform.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20151104005086/en/
The research collaboration will take phased approaches to
analyze retrospective samples from cancer patients with Asian
ancestry to identify the mutational profiles and their differences
from existing data of reference populations, which principally
contain data from individuals of Caucasian ancestry. In the first
phase of the project, SGH will perform a validation study using the
Ion Torrent PGM platform and the Oncomine Comprehensive Assay. The
project will then move to NGS-based prospective data analysis of
multiple cancers by using formalin fixed paraffin embedded (FFPE)
tissues and potentially other types of clinical samples to realize
the highest levels of data acquisition that will lead to new tests
with clinical actionability in the future.
"This collaboration with Singapore General Hospital underscores
our sustained commitment to serve our global customers in their
respective oncology research and clinical communities,” said Mike
Nolan, vice president and general manager of Oncology for Thermo
Fisher Scientific. “We will continue on this path of providing the
most advanced tools that add great value in the global effort to
manage cancer.”
“Investigating the differences in cancer gene mutations among
different populations is an essential factor in advancing
healthcare in a multiracial and multicultural society,” said Prof
Tan Puay Hoon, Head, Department of Pathology, SGH. “This
partnership will enable the oncology community to take steps
towards realising better and personalised care in the region.”
This research started in May and is part of the
POLARIS@SingHealth programme funded by A*STAR to enable
cutting-edge omics technologies and translating them for disease
diagnosis and treatment in Singapore in the future. This will be
actualized by establishing the necessary infrastructure and
resources, together with its clinical partners.
The project is supported in part by the Central R&D
organisation of the Life Sciences Solutions Group of Thermo Fisher
Scientific.
About Singapore General Hospital
Singapore General Hospital, a member of Singapore Health
Services, is the public sector's flagship hospital. Established in
1821, SGH is Singapore's largest acute tertiary hospital with 1,600
beds and national referral centre offering a comprehensive range of
36 clinical specialties on its campus. Every year, about 1 million
Singaporeans benefit from advanced medical care delivered by its
800 specialists. As an academic healthcare institution and the
bedrock of medical education, SGH plays a key role in nurturing
doctors, nurses and allied health professionals, and is committed
to innovative translational and clinical research in her continual
strive to provide the best care and outcomes to her
patients.www.sgh.com.sg
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world
leader in serving science, with revenues of $17
billion and approximately 50,000 employees in 50 countries.
Our mission is to enable our customers to make the world healthier,
cleaner and safer. We help our customers accelerate life sciences
research, solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Through our
premier brands – Thermo Scientific, Applied Biosystems, Invitrogen,
Fisher Scientific and Unity Lab Services – we offer an unmatched
combination of innovative technologies, purchasing convenience and
comprehensive support. For more information, please
visit www.thermofisher.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151104005086/en/
Thermo Fisher ScientificMauricio Minotta,
760-929-2456Mauricio.minotta@thermofisher.comorSingapore General
HospitalCarol Ang, +65-6321-4999carol.ang@sgh.com.sg
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Apr 2023 to Apr 2024